Close



Apr 18, 2024 08:03AM
Apr 18, 2024 08:00AM
Apr 10, 2024 04:19PM
Apr 10, 2024 04:02PM
Apr 10, 2024 04:01PM
Apr 1, 2024 08:09AM
Apr 1, 2024 08:00AM Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Mar 21, 2024 08:00AM
Mar 21, 2024 08:00AM
Feb 5, 2024 04:06PM
Feb 5, 2024 04:01PM
Feb 5, 2024 04:01PM
Jan 30, 2024 06:28AM
Jan 30, 2024 06:28AM Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
Jan 16, 2024 02:24PM
Jan 16, 2024 02:24PM
Jan 9, 2024 12:44PM
Jan 9, 2024 12:42PM
Jan 8, 2024 05:26AM
Jan 7, 2024 03:00PM
Dec 15, 2023 08:12AM Vertex Pharma (VRTX) Reports Positive CHMP Opinion for CASGEVY
Dec 15, 2023 08:12AM
Dec 12, 2023 03:21AM
Dec 11, 2023 07:30PM
Dec 8, 2023 12:55PM
Dec 8, 2023 12:52PM
Dec 8, 2023 12:09PM
Dec 8, 2023 11:20AM FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (CRSP) (VRTX) (BLUE)
Nov 24, 2023 09:13AM
Nov 24, 2023 09:13AM
Nov 16, 2023 04:53AM
Nov 16, 2023 01:45AM
Nov 6, 2023 04:01PM
Oct 3, 2023 06:01PM
Oct 3, 2023 06:01PM Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
Aug 1, 2023 04:01PM
Jun 23, 2023 06:55PM
Jun 9, 2023 05:35AM
Jun 9, 2023 05:29AM
Jun 9, 2023 03:01AM
Jun 8, 2023 07:23PM
May 4, 2023 05:31AM Vertex Pharma (VRTX) Announces FDA Approval of KALYDECO
May 3, 2023 05:07PM
May 1, 2023 04:01PM
Apr 28, 2023 09:07AM
Apr 26, 2023 01:37PM
Apr 26, 2023 01:37PM
Apr 3, 2023 08:01AM
Apr 3, 2023 08:00AM Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Th
Mar 16, 2023 08:06AM

251,888 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All